Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine · 07.12.2023 · 389 (23) · 2162-2174
DOI: 10.1056/nejmoa2309169 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 07.12.2023. Verfasst von Kathleen N Moore und 30 weiteren Autor:innen. Beteiligte Einrichtung: From the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Groupe Hosp…. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Maytansine, Ovarian Neoplasms. Die Arbeit wurde bisher 532-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: ImmunoGen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris (A.A.), Aix-Marseille Uni…
Förderung
- ImmunoGen
Zitieren
APA
Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J. Y., Moroney, J. W., Colombo, N., Roszak, A., Tromp, J., Myers, T., Lee, J. W., Beiner, M., Cosgrove, C. M., Cibula, D., Martin, L. P., Sabatier, R., Buscema, J., …, & Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups (2023). Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine, 389(23), 2162-2174. https://doi.org/10.1056/nejmoa2309169
Vancouver
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine. 2023;389(23):2162-2174. doi:10.1056/nejmoa2309169
BibTeX
@article{Moore2023,
author = {Moore, Kathleen N and Angelergues, Antoine and Konecny, Gottfried E and García, Yolanda and Banerjee, Susana and Lorusso, Domenica and Lee, Jung-Yun and Moroney, John W and Colombo, Nicoletta and Roszak, Andrzej and Tromp, Jacqueline and Myers, Tashanna and Lee, Jeong-Won and Beiner, Mario and Cosgrove, Casey M and Cibula, David and Martin, Lainie P and Sabatier, Renaud and Buscema, Joseph and Estévez-García, Purificación and Coffman, Lan and Nicum, Shibani and Duska, Linda R and Pignata, Sandro and Gálvez, Fernando and Wang, Yuemei and Method, Michael and Berkenblit, Anna and Bello Roufai, Diana and Van Gorp, Toon and Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups},
title = {Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {23},
pages = {2162--2174},
doi = {10.1056/nejmoa2309169}
}
EUVIMED